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Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S181symptoms (O2 requirement, RR > 24). ES characteristics and
consequences were compared for Maiolino and Spitzer
hybrid criteria (Maiolino criteria w/in 4d of ANC500 rather
than 24 hours of ﬁrst neutrophils) and Mayo Criteria (MC).
Pretransplant characteristics, ASCT complications, and the
dynamics of count recovery were all assessed.
Results: 146 (28%) had ES by MC while 48 (9%) had ES by
Maiolino Criteria. Patients with ES by MC experienced longer
hospital stays and received more IV antibiotics (Table 1).
Patients with ES were more likely to have amyloidosis,
a trend toward a higher pre-apheresis PB CD34+ count
(p¼0.053) and pre-apheresis PB WBC count (p¼0.052);
receive fewer days of G-CSF (P < 0.0001), and undergo
fewer apheresis sessions to meet collection goals (p¼0.012)
with more CD34+/kg collected per apheresis (p¼0.012).
They were also less likely to have undergone
chemomobilization. Too few patients perished within 30
days of ASCT (<1%) for meaningful statistical conclusions,
although, 5 patients died within 30d, 3 of whom ES may
have contributed. Patients with ES had shorter times to
ANC500 and ANC1000 (P < 0.0001) as well as from
WBC500 to ANC1000 (P < 0.0001). Patients on
corticosteroids for other reasons had fewer episodes of ES
(4% vs 29%; RR 0.133; P ¼ .003).
Conclusions: Mayo ES criteria were better able to identify
patients with increased resource utilization. As the rate of ES
was signiﬁcantly less in patients on corticosteroids for
reasons other than ES, it is possible that prophylaxis with low
doses of corticosteroids in patients at high risk of ES may
result in decreased IV antibiotics use and hospitalization.Table 1
Mayo
ES
No
Mayo
ES
P value Maiolino
ES
No
Maiolino
ES
P
value
Days of IV
antibiotics
11 8 <0.0001 10 10 0.28
Days hospitalized 6 0 <0.0001 3 2 0.69
Days before
dismissal home
20 20 0.65 19 20 0.2133
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Multiple myeloma (MM) remains a largely incurable disease
despite recent advances in biologic therapy. Autologous stem
cell transplant (ASCT) is the cornerstone of management yet
morbidity and transplant related mortality (TRM) remain
concerns for patients and physicians alike. Between October
2001 and June 2008, 21 MM patients underwent tandem
ASCT as part of a prospective phase II clinical study. After
initial ASCT, disease response was assessed at post-trans-
plant day 100 (D+100). Patients achieving very good partial
remission (VGPR) were offered maintenance therapy. If
patients achieved partial remission (PR), they were offered
a second autologous transplant (ASCT2) with a novel
conditioning regimen: Continuous IV cyclophosphamide
(CICy) 1500mg/m2/day on day -7 through day -4 followed by
and low dose total body irradiation (ldTBI) given twice dailyat 150 cGy on day -2 and -1. TBI was replaced by melphalan
140 mg/m2 if patients had received prior radiation. Median
duration of neutropenia with CICy/ldTBI was 10 days (range,
8-20). 15 patients (71.4%) developed febrile neutropenia.
After fever, grade 1-2 diarrhea was the most common non-
hematologic adverse event (42.9%). One patient each (4.8%)
developed a limited subdural bleed, pulmonary embolus,
neutropenic colitis, bacterial pneumonia, possible fungal
pneumonia, hemorrhagic cystitis, and septic shock. 19
patients (90.5%) required transfusion support (red blood
cells, platelets, or both) in the post-transplant period. All
patients were alive at D+100 with no treatment related
mortality. Three patients received CICY and melphalan. After
ASCT2, four patients had entered complete remission (CR)
(19.0%), seven achieved VGPR (33.3%), while six (28.6%) had
PR. At 4 years after enrollment of last patient, the median
progression free survival and overall survival was 21 (range,
7-101) and 38 (range, 12-128) months, respectively. In
conclusion, this novel conditioning regimen is safe and
effective alternative to high-dose melphalan, and may be
useful in patients who do not beneﬁt from ﬁrst ASCT using
other conditioning regimens.134
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In autologous hematopoietic stem cell transplantation
(ASCT), G-CSF administered from day +7 until ANC recovery,
expedites ANC recovery and reduces days of hospitalization
by 1-2 days. To determine whether delayed and abbreviated
G-CSF dosage could produce equivalent ANC recovery and
thereby improve cost effectiveness of ASCT for myeloma, we
delayed administration of G-CSF until WBC recovery had
begun and was 0.20/uL. G-CSF so administered was labeled
deferred G-CSF dosing (DGD), Patients in the conventional
dosing group (CGD) received daily doses of 5 mg/kg G-CSF
beginning day +7. The primary and secondary end points are
listed in table-1. The Institutional Review Board approved
retrospective chart analysis
A total of 117 patients with multiple myeloma received
ASCT from January 2005 to September 2012. Of these, 65
patients received DGD and 52 received CGD. Patient, disease,
and transplant-related variables were similar between 2
groups; patients in DGD received a larger dose of CD34+
cells/kg (median 4.49, range¼ 2.49-10.2 vs. median 3.79,
range ¼ 2.61-9.42, p¼ 0.021)
The CGD group received a median of 5 doses of G-CSF,
while the DGD group received, a median of 0 (range 0-5,
P  .0001) G-CSF doses (5mg/kg) when the WBC were
